Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013918 | 1.00 | FABP5 (0.44) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL4896949 | 0.98 | FABP5 (0.45) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL28659758 | 0.98 | FABP5 (0.45) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL11902423 | 0.94 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL20681006 | 0.94 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL4736280 | 0.85 | KMT2A (0.40) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL4736278 | 0.85 | KMT2A (0.40) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL29913804 | 0.81 | FABP5 (0.47) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL11964044 | 0.81 | KMT2A (0.48) | FABP5FABP7KMT2AEPHX2 | |
| SCHEMBL16095352 | 0.80 | FABP5 (0.46) | FABP5FABP7KMT2ACASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732286-A2 | COMPOSITIONS AND METHODS FOR ENCRYPTING, STORING, AND DECRYPTING INFORMATION IN OLIGOMERS | Board of Regents, The University of Texas System (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025058677-A2 | COMPOSITIONS AND METHODS FOR ENCRYPTING, STORING, AND DECRYPTING INFORMATION IN OLIGOMERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-118812647-B | Novel insect short neuropeptide sNPF analogue and application thereof | 四川轻化工大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-113544138-B | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118812647-A | Novel insect short neuropeptide sNPF analogue and application thereof | 四川轻化工大学 | 2024-10-22 | — | — | CN | disclosed |
| US-20240336654-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Universität Zürich (CH) | 2024-10-10 | — | — | US | disclosed |
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-4339204-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-03-20 | — | — | EP | disclosed |
| EP-4041880-A1 | MUTANT DNASE1L3 WITH IMPROVED SERUM HALF-LIFE | Texas Tech University System (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2000023421-A1 | (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000001666-A1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| US-5990112-A | 6-MERCAPTOMETHYL-PIPERAZIN-2,5-DIONE DERIVATIVES; USEFUL FOR TREATING OR CONTROLLING DISEASE STATES OR CONDITIONS WHICH INVOLVE TISSUE BREAKDOWN, SUCH AS RHEUMATOID ARTHRITIS | AFFYMAX TECHNOLOGIES N.V. (GB) | 1999-11-23 | — | — | US | disclosed |
| US-5932579-A | ANTIARTHRITIC AGENTS; CONTROLLING TISSUE DEGRADATION | AFFYMAX TECHNOLOGIES N.V. (GB) | 1999-08-03 | — | — | US | disclosed |
| WO-1998042656-A1 | NOVEL COMPOUNDS | CYTEL CORPORATION (US) | 1998-10-01 | — | — | WO | disclosed |
| WO-1997048685-A1 | METALLOPROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| US-5614370-A | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1997-03-25 | — | — | US | disclosed |
| WO-1995025957-A1 | HUMAN C5a ANTAGONISTS AND AGONISTS | MERCK & CO., INC. (US) | 1995-09-28 | — | — | WO | disclosed |
| US-5128448-A | Peptide hormones | HOFFMAN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
| WO-1992004370-A1 | MODIFIED DI- AND TRIPEPTIDYL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | KRAS, G3BP1, G3BP2 | FABP5 1054/4885FABP7 1115/4885KMT2A 3256/4885 |
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | FABP5 567/4885FABP7 497/4885KMT2A 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.